top of page

London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings

  • blonca9
  • Nov 20, 2024
  • 1 min read

CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully developing an oral therapy could set Pharvaris apart.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page